Skip to main
EXAS

Exact Sciences (EXAS) Stock Forecast & Price Target

Exact Sciences (EXAS) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 28%
Hold 39%
Sell 0%
Strong Sell 0%

Bulls say

Exact Sciences is poised for significant growth, with expectations of Cologuard, its flagship colorectal cancer screening test, achieving an increase in market share from approximately 15% to a long-term goal of over 40%. The company reported a remarkable 22% year-over-year growth in its core screening business during Q3 2025 and raised its 2025 revenue guidance, reflecting strong demand and higher average selling prices for Cologuard Plus. Additionally, the launch of the Cancerguard blood test, targeting over 50 cancer types, is anticipated to contribute incrementally to sales and marketing efforts, further enhancing the company's financial trajectory.

Bears say

The analysis indicates that Exact Sciences is facing challenges in sustaining profitability, as evidenced by its history of net losses and uncertainty regarding the achievement of GAAP profitability. Additionally, the demand for its Cologuard test is highly dependent on marketing spending, suggesting that the company's revenue may be vulnerable to fluctuations in promotional activities. Furthermore, revenue estimates for 2027 fall short of targets, raising concerns about growth potential despite potential benefits from new licensing agreements and expected increases in demand for its diagnostic products.

Exact Sciences (EXAS) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 28% recommend Buy, 39% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exact Sciences (EXAS) Forecast

Analysts have given Exact Sciences (EXAS) a Buy based on their latest research and market trends.

According to 18 analysts, Exact Sciences (EXAS) has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $81.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $81.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exact Sciences (EXAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.